Blog from IFPMA ADG Greg Perry following his visit to Cabo Verde
Find out here an insight that Greg Perry gives around WHO Afro Global Health Forum 2019
Read More
Thought Leader Series in Vaccines
A mustread from experts talking about the value of vaccines
Read More
Our response to Zika virus
Check here about the R&D blueprint against Zika
Read More
Women’s Cancer Initiative in the Americas
Partnership to improve prevention of women’s cancers and quality of cancer registries in LAC reaches 1 year milestone
Read More
Latest News
2020-03-19 09:51:38
Global Biopharmaceutical Industry pulling out all the stops to address Coronavirus public health crisis
19 March 2020, Geneva – The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), representing the world’s leading biopharmaceutical companies, ...
Read More2020-03-16 10:30:47
Pharma industry and patient groups collaborate on a NEW guidance note on best practices for interaction
Geneva, March 17, 2020 – The International Association of Pharmaceutical Manufacturers and Associations (IFPMA) and ...
Read More2019-10-25 05:13:16
Global Health Progress launched to drive cross-sectoral collaborations in support of the Sustainable Development Goals (SDGs)
Global Health Progress is a new knowledge hub highlighting over 200 collaborations between the innovative ...
Read More2019-01-10 07:49:44
R&D biopharmaceutical industry embraces NEW Code of Practice to boost business integrity worldwide
The new Code of Practice in place from 1 January 2019, imposes a complete ban ...
Read More2018-12-10 13:14:17
Unjela Kaleem joins global pharma association as Director of Communications
Geneva, 10 December 2018 – IFPMA, the global research-based biopharmaceutical industry association, is pleased to ...
Read More2018-12-05 12:00:49
R&D biopharmaceutical industry revamp ethical code to apply as base line of industry behavior worldwide
New R&D biopharmaceutical industry Code of Practice comes into effect on 1 January 2019. Changes ...
Read More2018-12-04 17:17:22
David A. Ricks Elected New President of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly and Company, takes over as ...
Read More2020-03-19 09:49:06
Global Biopharmaceutical Industry Commitment to Address Coronavirus Public Health Crisis
David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly ...
Read More2020-02-12 18:32:08
IFPMA and WHO Global Research and Innovation Forum
David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly ...
Read More2020-02-10 07:39:58
IFPMA Members' support in countering the novel coronavirus (2019-nCoV)
David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly ...
Read More2020-02-07 16:43:11
WHO EB 146 Agenda Item 20: Data and innovation: draft global strategy on digital health
David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly ...
Read More2020-02-07 16:01:28
WHO EB 146 Agenda Items 15.3: Influenza preparedness and 15.4: The public health implications of implementation of the Nagoya Protocol
David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly ...
Read More2020-02-07 15:04:08
WHO EB 146 Agenda Item 13: Neglected tropical diseases
David A. Ricks, Chairman and Chief Executive Officer, Eli Lilly ...
Read More
mailto:s.kaenzig@ifpma.org +41 22 338 32 49
direct line
Twitter skaenzig
Sadia Kaenzig - Communications Manager
Sadia manages communications on issues including regulatory, intellectual property protection, trade and the economic footprint of the research-based pharmaceutical industry, research and development ecosystem and innovation, vaccines including influenza vaccines, and biotherapeutics.
mailto:m.depol@ifpma.org +41 22 338 32 20
direct line
Twitter @MorganePol
Morgane De Pol - Communications and Public Affairs
Morgane manages communications on issues including the research-based pharmaceutical industry’s commitment to achieving sustainable and inclusive development, advancing Universal Health Coverage, designing transformational partnerships to build healthier societies, boosting innovation for neglected tropical diseases, expanding access to high quality treatments for infectious and chronic diseases, fighting counterfeit medicines, and promoting resilient and efficient health systems.
Our Brouchure
2015 Edition
A shared commitment to global health
At IFPMA we advocate policies and practices that encourage the discovery of and access to life-saving and life-enhancing medicines and vaccines, for people everywhere.
Our Logo
Full colour EPS format
Our Logo
Full colour PNG format
FULL Name LOGO
Full colour EPS format
FULL Name LOGO
Full colour PNG format
Hot Topic
Pharmacovigilance: Do your bit, play your part!
Pharmacovigilance is one of the key steps to ensuring the safety of all our medicines, including biotherapeutics and vaccines. It encourages an ongoing cycle of communication between patients, health professionals, regulatory authorities, and our biopharma industry which is
Read MoreInterview
IFPMA 2015 interview series 'Biodiversity, human health, and pharma'
A must-watch: Dr Manisha A. Desai, assistant general patent counsel at Eli Lilly and Company, gives her take on the importance of the Convention of Biodiversity and the Nagoya Protocol for the pharma industry. What's key is to
Read MoreOur Blog
Interview - BBC World Newshour - Biopharmaceutical industry commitments on COVID-19
Thomas Cueni, IFPMA Director General, spoke to BBC Newshour on 19 March about the commitments made by the global pharmaceutical industry in addressing the COVID-19 global health crisis. Industry has the tools and solutions to fight and defeat the novel strain of coronavirus. In this unique situation, industry commits to tackle this issue collaboratively - not just among the industry, but with WHO and with other health agencies. There has already been an intense and...
Read More
The global biopharmaceutical industry’s united front against COVID-19
In recent weeks, we have seen an unprecedented rapid response from governments, international organisations, health care professionals, the biopharmaceutical industry and many others to respond to one of the biggest global health crisis the world has experienced in recent decades: the novel coronavirus, or so-called COVID-19. Both professionally but also personally I think it's remarkable how far we have come in two months. R&D efforts...
Read More
Beyond childhood: the case for life-course immunisation
This was originally published in Health Awareness UK on Thursday, March 19, 2020. Is it possible to protect all populations from certain diseases, while keeping health system expenses within a reasonable range? Let’s look at implementing a life-course approach to immunisation… The global population continues to age. In 2020, children under five years will be outnumbered by people of 60 or more years. This means prevention...
Read MoreLatest Tweets
